Clinical Trial Update: Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of letrozole and trastuzumab (Herceptin) in HER2-positive, ER/PR-positive metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Letrozole (letrozole)

Snippet

Sponsor: Duke University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED